Marc Ditmarsch
Corporate Officer/Principal bij FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Vermogen: - $ op 30-04-2024
Profiel
Marc Ditmarsch is currently the Vice President-Research & Development at NewAmsterdam Pharma Holding BV and the Chief Development Officer at NewAmsterdam Pharma Co. NV.
Previously, he worked as a Medical Director at AstraZeneca BV from 2014 to 2016.
He holds a doctorate degree from Vrije Universiteit Amsterdam.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 22-03-2023 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Marc Ditmarsch
| Bedrijven | Functie | Begin |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Corporate Officer/Principal | 01-08-2022 |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Corporate Officer/Principal | 01-01-2020 |
Eerdere bekende functies van Marc Ditmarsch
| Bedrijven | Functie | Einde |
|---|---|---|
| AstraZeneca BV | Hoofd Techniek/Wetenschap/O&O | 01-01-2016 |
Opleiding van Marc Ditmarsch
| Vrije Universiteit Amsterdam | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| AstraZeneca BV | |
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Health Technology |
